AACR Annual Meeting | Conference

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Dr. Anderson on Overcoming Suppressive Signals by Engineering T-cells in Ovarian Cancer

April 12th 2022

Kristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

April 12th 2022

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors

April 12th 2022

MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.

Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models

April 12th 2022

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Dr. Gulati on the Prevalence of TSC1 and TSC2 Mutations in Solid Tumors

April 12th 2022

Gunsagar Gulati, MD, discusses the prevalence of TSC1 and TSC2 mutations in solid tumors.

Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors

April 12th 2022

The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.

Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL

April 12th 2022

Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.

CoVac-1 Vaccination Could Prevent Severe COVID-19 in Patients with Cancer and Immunoglobulin Deficiency

April 12th 2022

CoVac-1, a multi-peptide COVID-19 vaccine, elicited promising T-cell activity and safety in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.

SCC244 Elicits Responses in METex14 Skipping–Mutated NSCLC

April 12th 2022

SCC244, a highly selective MET inhibitor, demonstrated durable efficacy in patients with non–small cell lung cancer who harbored MET exon 14 skipping mutations.

Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC

April 12th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.

ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma

April 12th 2022

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL

April 12th 2022

The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.

gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC

April 11th 2022

High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors

April 11th 2022

The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.

ZD5305 Proves Favorable to First-Generation PARP Inhibitors Across Different Cancer Types

April 11th 2022

AZD5305, a next generation PARP inhibitor, produced favorable safety and clinical activity vs first-generation PARP inhibitors in patients with multiple different cancer types.

Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC

April 11th 2022

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC

April 11th 2022

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.